Tenofovir-BVP medicine for HIV and HIEB resistance treatment, hepatitis B (3 blisters x 10 tablets)

Dosage form Box of 3 blisters x 10 tablets
Specifications Tenofovir disoproxil

Ingredient

Composition information	Content
Tenofovir disoproxil	300mg

Uses

Indications

Tenofovir - BVP is indicated in the following cases:

Preventing HIV infection after exposure to the disease, treating chronic hepatitis B in adults.

Pharmacokic

tenofovir disoproxil fumarate is a nucleotid ester -free nucleotid -like nucleotid ester monophosphate and has a molecular structure close to Adefovir Dipivoxil, Tenofovir Disoproxil Fumarat needs to undergo the initial hydrolysis of the initial transition into the Tenofir and follow the Tenofir and the following process Phosphorylation remedies the enzymes in the cell to form a substance with the active substance of tenofovir diphosphate.

Tenofovirdiphosphate inhibits the activity of the HIV1 transcription enzyme by competing with the natural substrate of Deoxyadenosin - 5 Triphosphate and after cohesion to DNA, causing the end of the DNA chain. In addition, Tenofovir Disoproxil Fumarat also inhibits the DNA polymerase of the virus that causes hepatitis B (HBV), an essential enzyme for the virus to copy in liver cells. Tenofovir is a weak inhibitor A&P - DNA polymerase of mammals and T - DNA polymerase enzymes in vertebrates.

pharmacokinetics

The drug is quickly absorbed after taken and converted into Tenofovir. Peak concentration in plasma is achieved after 1-2 hours. Birth is about 25% but increased when used with a fat -rich meal. Tenofovir is widely distributed in tissues, especially in the kidneys and liver, the cohesion of plasma protein is 1% lower and with serum protein about 7%. Selling time is from 12 - 18 hours. Excretion mainly through urine in both ways, excreted through the renal tubules and glomerular filter, Tenofovir can be eliminated by hemolysis.

Before taking Tenofovir-BVP medicine for HIV and HIEB resistance treatment, hepatitis B (3 blisters x 10 tablets)

How to use

Tenofovir drugs are taken orally.

Dosage

HIV infection treatment

1 tablet, 1 time a day, combined with other antiviral drugs.

Preventive HIV prevention after exposure due to occupational causes

1 tablet, 1 time daily combined with other antiviral drugs (usually combined with lamivudin or emtricitabin). Prevention should start as soon as possible after contact (preferably within hours than a few days) and continue for the next 4 weeks if tolerated.

Preventive HIV infection is not due to occupational causes

1 tablet, 1 time a day combined with at least 2 other antiviral drugs. The provision should start as soon as possible (best within 72 hours) and continue for 28 days.

Chronic hepatitis B cisability

1 tablet, once a day for more than 48 weeks.

Patients with renal failure

Needs to reduce the dose by adjusting the duration of the drug.

Creatinine clearance

Medication distance Now

7 days or 12 hours after the appraisal.

Patients with liver failure

No need to adjust the dose.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.

What to do when overdose? If an overdose occurs, it is necessary to monitor the signs of poisoning, if necessary, the basic supportive treatment should be applied. Tenofovir is eliminated effectively through hemolysis with a separation coefficient of about 54%. With a single dose of 300 mg, a 4 -hour jurgle can be excluded about 10% of the dose.

What to do when forgetting a dose? However, if close to the next dose, skip the forgotten dose and take the next dose at the time as planned. Note that it should not be used double the prescribed dose.

Side Effects

When using Tenofovir - BVP, you may experience unwanted effects (ADR).

The most common side effects are mild disorders on the gastrointestinal tract, especially diarrhea, nausea, vomiting, abdominal pain, flatulence, indigestion, anorexia.

Hypergathic hyperglycemia, pancreatitis.

Hemorrhagic reduction also occurs.

skin rash.

Peripheral neuropathy, headache, dizziness, insomnia, depression, weakness, sweating and muscle pain.

Hyper enzyme hyper enzyme, hyper triglycerides, hyperglycemia and neutrophils.

Renal failure, acute renal failure and the effects on the close tube, including fanconi syndrome.

Lactic acid infection, usually combined with heavy liver and fatty liver.

Instructions on how to handle ADR

Notify the doctor with unwanted effects when using the drug.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

Tenofovir - BVP is contraindicated in the following cases:

Hypersensitivity to Tenofovir Disoproxil Fumarate or any ingredient of the drug.

Be cautious when using

When using Retrovirus anti -drugs may increase fat life caused by redistribution or fat accumulation in the body, including: Central obesity, antipyretic front back (hunchback), peripheral nervous destruction, face, mammary glands, Cushing syndrome.

Use Tenofovir at the same time with lamivudin and Efavirenz that can reduce the mineral density of the lumbar spine, increasing the concentration of 4 factors of bone metabolism, increasing serum parathyroid hormones in serum. Correct bone monitoring in patients with a history of fractures or at risk of osteoporosis, supplementing with calcium and vitamin D is useful, although the effect has not been proven. If you suspect there are bone abnormalities, you need to consult your doctor.

The ability to drive and operate machinery

No research shows the effect of the drug affects the ability to drive and operate machinery. However, it is necessary to notify the patient about the ability to cause dizziness when treating with this drug.

Pregnancy

only use drugs for pregnant women when the benefits of treatment outstanding risks may occur for the fetus. Women of reproductive age should be accompanied by effective methods of contraception due to the ability to increase the conception of the drug.

Breastfeeding period

Do not take medicine for women during breastfeeding. According to general recommendations, HIV -infected women should not breastfeed to avoid HIV infection for babies.

Drug interaction

drugs affected or metabolized by liver enzymes

The pharmacokinetic interaction of tenofovir with inhibitors or substrates of liver enzymes is not sure. Tenofovir and precursors are not CYP substrate, do not inhibit the isomers 3A4, 2D6, 2C9 or 2E1 but slightly inhibit the slightly on 1A.

Medications are influenced or eliminated through the kidneys

Tenofovir interacts with drugs that reduce kidney function or competition eliminated through the renal tubules (such as: Acyclovir, Cidofovir, Ganciclovir, Valacyclovir, Valganiclovir), increasing plasma tenicovir concentrations or shared drugs.

HIV protease inhibitors

There is a combination of force between Tenofovir and HIV protease inhibitors such as Amprenavir, Atazanavir, Indinavir, Ritonavir, Saquinavir.

Nucleosid -free enzyme inhibitors

There is a synergistic effect between Tenofovir and Nideosid reverse copy inhibitors such as Delavirdin, Efavirenz, Nevirapin.

Nucleosid backward enzyme inhibitors

There is a synergistic effect between Tenofovir and nideosid reverse transcription inhibitors such as abacavir, leftin, emtricitabin, lamivudin, stavudin, zalcitabin, zidovudin.

Oral contraceptives

Dynamic interaction with oral contraceptives containing Ethinyl Estradiol and Norgestimat is unknown.

Storage

temperature does not exceed 30 ° C, avoid moisture.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.